Physician profile
Mohammed Munir
NPI 1881631844
$2,720.74
in general payments reported to CMS, 2019-2025
17 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $144 · 2021: $124 · 2023: $29.90 · 2024: $193 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $719 · Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $718.91 |
| Food and Beverage | $582.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $956.54 | 2025 | |
| Allergan, INC. | $396.44 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $338.11 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $246.60 | 2019-2024 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $137.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $122.11 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $104.79 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.77 | 2019 | |
| Abbvie INC. | $77.22 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.81 | 2021-2023 | |
| Lundbeck LLC | $59.99 | 2019-2020 | |
| Shire North American Group INC | $46.12 | 2019 | |
| Neuronetics, INC. | $45.05 | 2019 | |
| Alkermes, INC. | $13.59 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.